Gynecomastia is very rare during antituberculosis chemotherapy. We describe a 38-year-old male patient who developed a painful gynecomastia following second-line drug therapy for multidrug-resistant pulmonary tuberculosis. Gynecomastia... more
Gynecomastia is very rare during antituberculosis chemotherapy. We describe a 38-year-old male patient who developed a painful gynecomastia following second-line drug therapy for multidrug-resistant pulmonary tuberculosis. Gynecomastia disappeared after stopping the ethionamide. A published literature on antituberculosis-induced gynecomastia is also briefly discussed.
Accurate diagnosis of tuberculosis (TB) is crucial to facilitate early treatment of the patients, and to reduce its spread. Clinical presentation of Mycobacterium tuberculosis complex (MTBC) and non tuberculous mycobacteria (NTM) may or... more
Accurate diagnosis of tuberculosis (TB) is crucial to facilitate early treatment of the patients, and to reduce its spread. Clinical presentation of Mycobacterium tuberculosis complex (MTBC) and non tuberculous mycobacteria (NTM) may or may not be the same, but the treatment regimen is always different for both the infections. Differentiation between MTBC and NTM by routine laboratory methods is time consuming and cumbersome. This study was aimed to evaluate an immunochromatographic test (ICT), based on mouse monoclonal anti-MPT64, for simple and rapid discrimination between MTBC and NTM in clinical isolates from extra-pulmonary tuberculosis cases. A total of 800 clinical samples were collected from patients suspected to have extra-pulmonary tuberculosis. Preliminary diagnosis has been done by direct Ziehl-Neelsen (ZN) staining followed by culture in BACTEC system. A total of 150 clinical isolates, which were found positive in BD 460 TB system during September 2009 to September 2010...
Research Interests:
ADAM33 is a member of a family of genes that encode membrane-anchored proteins with a disintegrin and a metalloprotease domain, primarily expressed in lung fibroblasts and bronchial smooth muscle cells. ADAM33 has been identified as a... more
ADAM33 is a member of a family of genes that encode membrane-anchored proteins with a disintegrin and a metalloprotease domain, primarily expressed in lung fibroblasts and bronchial smooth muscle cells. ADAM33 has been identified as a risk factor for asthma and is known as a gene associated with airway remodelling. The present study was conducted with the aims to investigate the expression of ADAM33 protein in patients of asthma and non-asthmatic controls, and to assess if the expression of ADAM33 protein relates with severity of asthma. A total of 35 subjects, including 27 patients with asthma and eight non-asthmatic controls were included using Global Initiative for Asthma guidelines 2005. Bronchial biopsy tissues were collected and paraffin sections were made to store all study samples. Immunohistochemistry was performed using standardized protocol. An increase in expression of ADAM33 protein was observed in the epithelium, smooth muscle and mesenchymal cells of asthma cases when...
Research Interests: Asthma, Biopsy, Prospective studies, Humans, Female, and 4 moreMale, Middle Aged, Adult, and Gene Expression Regulation
As Internet technology becomes more pervasive, homes are getting connected to Cable or DSL. The increasing user demands for always on service along with multiple con-nectivity for Voice and Data is gradually making presence of... more
As Internet technology becomes more pervasive, homes are getting connected to Cable or DSL. The increasing user demands for always on service along with multiple con-nectivity for Voice and Data is gradually making presence of Residential Gateway in every ...
Research Interests:
Pulmonary tuberculosis is endemic globally and is responsible for considerable morbidity and mortality. India is classified among the 22 high burden countries by WHO. According to WHO global TB report 2015 incidence of TB in India in 2014... more
Pulmonary tuberculosis is endemic globally and is responsible for considerable morbidity and mortality. India is classified among the 22 high burden countries by WHO. According to WHO global TB report 2015 incidence of TB in India in 2014 was 2.2 million (including patients with HIV/TB) while, prevalence was 2.5 million (includes patients with HIV/TB). Mortality (excluding patients wit HIV/TB) was 0.2 million and case detection for all forms of TB was approximately 74%. With the emerging threat of Drug-Resistant TB, We need to improve our surveillance and treatment facility to eliminate TB by 2050.